Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer. Given the large body of new evidence addressing the management of cervical cancer, the three sister societies jointly decided to update these evidence-based guidelines. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment in cervical cancer.To serve on the expert panel (27 experts across Europe) ESGO/ESTRO/ESP nominated practicing clinicians who are involved in managing patients with cervical cancer and have demonstrated leadership through their expertise in clinical care and research, national and international engagement, profile, and dedication to the topics addressed. To ensure the statements were evidence based, new data identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Before publication, the guidelines were reviewed by 155 independent international practitioners in cancer care delivery and patient representatives.These updated guidelines are comprehensive and cover staging, management, follow-up, long-term survivorship, quality of life and palliative care. Management includes fertility sparing treatment, early and locally advanced cervical cancer, invasive cervical cancer diagnosed on a simple hysterectomy specimen, cervical cancer in pregnancy, rare tumors, recurrent and metastatic diseases. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247855PMC
http://dx.doi.org/10.1007/s00428-023-03552-3DOI Listing

Publication Analysis

Top Keywords

cervical cancer
28
patients cervical
12
european society
12
guidelines management
8
management patients
8
cervical
8
cancer
8
evidence-based guidelines
8
management
6
guidelines
5

Similar Publications

Background: Human papillomavirus (HPV) testing is the primary method for cervical cancer screening, but reliable detection depends on adequate sample cellularity. Cycle threshold (Ct) values for the assay's internal control (IC), such as β-globin, are commonly used as proxies for adequacy, yet standardized Ct cut-offs are lacking. We aimed to contribute evidence-based thresholds for sample adequacy using real-world data.

View Article and Find Full Text PDF

Ferroptosis resistance is a key player in cervical cancer (CC) development. Hypoxia is a negative factor affecting CC treatment by inducing ferroptosis resistance. Our study aimed to investigate the detailed mechanisms of hypoxia-induced ferroptosis resistance in CC cells.

View Article and Find Full Text PDF

Introduction: Despite high coverage of routine childhood vaccines, uptake of the human papillomavirus (HPV) vaccine in the Pacific Island nation of Tonga has been slow. Culturally appropriate communication resources on the importance, safety, and effectiveness of the HPV vaccine are critical to support acceptance and uptake. To develop these resources, it is important to understand what people want to know.

View Article and Find Full Text PDF

This study aims to examine the effect of education interventions given to women with religious orientation on cervical cancer and Pap smear test health beliefs.The study used a quasi-experimental research design with the pre-test-post-test control group. It was conducted in Qur'an courses in a province in eastern Turkey between January and October 2023.

View Article and Find Full Text PDF

PD-L1 expression in locally advanced cervical cancer: A pilot cross clone comparison study.

Int J Radiat Oncol Biol Phys

September 2025

Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Electronic address:

Purpose: Recent immunotherapy trials in locally advanced cervical cancer report high PD-L1 positivity rates whereas academic multicentric initiatives report a lower PD-L1 positivity. These observations necessitate cross-clone comparison to understand the observed differences.

Methods: Two different clones used in previous multicentric international studies SP142 (BIOEMBRACE) and 22C3 (KEYNOTE-A18) were used to test PD-L1 positivity in a pilot cohort of FIGO 2018 stage III cervical cancer patients recruited in a phase III trial.

View Article and Find Full Text PDF